Drug maker Lupin on Friday said it has received approval from the U.S. health regulator to market a generic medication to treat bacterial infections, in America.
The company has received approval from the U.S.FDA for Doxycycline for Injection USP, the Mumbai-based drug maker said in a statement.
The company's product is the generic equivalent of Pfizer Inc's Vibramycin for injection, it added.
The product will be manufactured at its Nagpur facility, Lupin said.
ADVERTISEMENT
Doxycycline for Injection USP is indicated to reduce the development of drug-resistant bacteria.
As per the IQVIA MAT January 2024 data, Doxycycline for Injection USP had estimated annual sales of $47 million in the U.S. market.
ADVERTISEMENT
RECOMMENDED FOR YOU
Stocks To Buy, Sell, Or Hold: Shrikant Chouhan's Insights On SBI, Lupin And Gujarat Narmada
Jul 02, 2025
Lupin To Spin Off Healthcare Division
Jul 01, 2025
Novo Nordisk Launches Weight-Loss Drug Wegovy In India Starting From Rs 17,300
Jun 24, 2025
RBI Discontinues VRR Auctions As Liquidity Stabilises
Jun 09, 2025
POPULAR
1
Stock Market Today: Nifty, Sensex End Little Changed As Investors Await Trade Deal Clarity
2
Sudha Murty's 'How I Taught My Grandmother To Read' To Be Adapted Into Play
3
8th Pay Commission Setup Further Delayed? DoPT Circular On Appointments Sparks Concern
4
ICICI Bank, Muthoot Finance, Aptus — Dolat Capital Lists Top Stock Picks In BFSI Space; Q1 Results Preview
5